neuroinflammation – mycolab.ai

Neuroprotective effects of psilocybin in a rat model of stroke

mycolabadmin

Scientists studied whether psilocybin, the active compound in magic mushrooms, could protect the brain from stroke damage in rats. They found that psilocybin reduced brain damage, improved movement and behavior recovery after stroke, and worked by increasing a protective brain chemical called BDNF. This research suggests psilocybin could become a new treatment for stroke patients, especially since stroke often leads to depression and anxiety, which psilocybin may also help treat.

Fungal Bioactive Compounds as Emerging Therapeutic Options for Age-Related Neurodegenerative Disorders

mycolabadmin

Mushrooms contain special compounds that may help protect our brains as we age. These fungal compounds fight inflammation, reduce harmful free radicals, and help clear out damaged cellular parts—all things that slow down brain aging and diseases like Alzheimer’s and Parkinson’s. While the research looks very promising in lab and animal studies, scientists still need to figure out how to make these compounds work better in the human body and prove they’re safe and effective in patients.

Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review

mycolabadmin

This review explores how medicinal mushrooms may help fight depression through several natural mechanisms. These mushrooms contain compounds that boost serotonin production, reduce brain inflammation, and promote healthy neural growth. The review also discusses psilocybin from magic mushrooms as a promising rapid-acting treatment for severe depression that doesn’t respond to conventional medications.

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity

mycolabadmin

This review examines how psilocybin, the active compound in certain mushrooms, may help treat depression and anxiety by reducing brain inflammation and promoting healthy neurotransmitter function. Both full doses under medical supervision and smaller ‘microdoses’ show promise for mental health conditions. The research suggests psilocybin works by calming the immune system’s inflammatory response while simultaneously supporting the brain’s natural healing and adaptation processes, offering a potential alternative treatment when standard medications don’t work.

Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation

mycolabadmin

Depression is a serious mental health condition affecting over 300 million people worldwide, with many patients not responding well to standard antidepressants. This review examines both traditional antidepressants like SSRIs and exciting new treatments including ketamine and psilocybin, as well as brain stimulation techniques. The key finding is that different treatments work through similar mechanisms—all ultimately enhancing brain cell connections and reducing inflammation—suggesting that combining different approaches might work better than single therapies.

Impact of Hericium erinaceus and Ganoderma lucidum metabolites on AhR activation in neuronal HT-22 cells

mycolabadmin

This study examined how two medicinal mushrooms, lion’s mane and Reishi, affect nerve cells in the brain. The researchers found that metabolites from these mushrooms don’t harm brain cells and actually boost protective proteins that support cell health and survival. The mushrooms appear to work through a cellular receptor called AhR, which helps facilitate communication between the gut and the brain. These findings suggest that these mushrooms may help support brain function and protect against neurological problems.

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia

mycolabadmin

Schizophrenia involves excessive loss of connections between brain cells in areas responsible for emotion and thinking, leading to negative symptoms and cognitive problems. Research shows that small doses of psychedelics like psilocybin can promote the growth of new brain connections and reduce inflammation. The authors suggest that microdosing psychedelics alongside standard treatments might help restore these lost connections and improve symptoms that don’t respond well to current medications.

Neuroprotective Effect of Mixed Mushroom Mycelia Extract on Neurotoxicity and Neuroinflammation via Regulation of ROS-Induced Oxidative Stress in PC12 and BV2 Cells

mycolabadmin

A mixture of three medicinal mushrooms (Phellinus linteus, Ganoderma lucidum, and Inonotus obliquus) was tested for its ability to protect nerve cells from damage. The extract successfully reduced cell death in laboratory models of neurodegeneration by reducing harmful molecules called reactive oxygen species and reducing inflammation. These results suggest the mushroom extract could potentially help prevent or slow neurological diseases like Alzheimer’s.

The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study

mycolabadmin

A 70-year-old man suffering from severe depression and anxiety caused by chronic Lyme disease and related tick-borne infections found relief after taking small doses of psilocybin mushrooms three times a week. Within days of starting treatment, his mood improved dramatically, and he remained symptom-free for two years. This case suggests that psilocybin’s ability to reduce inflammation in the brain may help patients with infectious-caused psychiatric conditions who cannot tolerate standard medications.

The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice

mycolabadmin

This study tested whether psilocybin (an active compound from magic mushrooms) combined with eugenol (a natural compound from cloves) could reduce brain inflammation in mice. Researchers gave mice a substance that triggers inflammation in the brain and then treated them with these compounds before or after the inflammation started. The combination treatment, especially at a 1:50 ratio of psilocybin to eugenol, significantly reduced multiple inflammatory markers in the brain, suggesting this combination could potentially be helpful for treating brain inflammation-related conditions.

Research Topic: neuroinflammation